PL3452100T3 - Nośniki farmaceutyczne zawierające mirna do zastosowania w leczeniu chorób zwłókieniowych spowodowanych hiperglikemią - Google Patents

Nośniki farmaceutyczne zawierające mirna do zastosowania w leczeniu chorób zwłókieniowych spowodowanych hiperglikemią

Info

Publication number
PL3452100T3
PL3452100T3 PL17725186T PL17725186T PL3452100T3 PL 3452100 T3 PL3452100 T3 PL 3452100T3 PL 17725186 T PL17725186 T PL 17725186T PL 17725186 T PL17725186 T PL 17725186T PL 3452100 T3 PL3452100 T3 PL 3452100T3
Authority
PL
Poland
Prior art keywords
hyperglicemia
fiberatal
mirn
treatment
diseases caused
Prior art date
Application number
PL17725186T
Other languages
English (en)
Inventor
Maria Felice Brizzi
Giovanni Camussi
Original Assignee
Unicyte Ev Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unicyte Ev Ag filed Critical Unicyte Ev Ag
Publication of PL3452100T3 publication Critical patent/PL3452100T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Botany (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Optics & Photonics (AREA)
PL17725186T 2016-05-06 2017-05-04 Nośniki farmaceutyczne zawierające mirna do zastosowania w leczeniu chorób zwłókieniowych spowodowanych hiperglikemią PL3452100T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16168546 2016-05-06
PCT/EP2017/060612 WO2017191234A1 (en) 2016-05-06 2017-05-04 Pharmaceutical carriers containing mirnas for use in the treatment of fibrotic diseases caused by hyperglycemia
EP17725186.5A EP3452100B1 (en) 2016-05-06 2017-05-04 Pharmaceutical carriers containing mirnas for use in the treatment of fibrotic diseases caused by hyperglycemia

Publications (1)

Publication Number Publication Date
PL3452100T3 true PL3452100T3 (pl) 2021-07-19

Family

ID=56008484

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17725186T PL3452100T3 (pl) 2016-05-06 2017-05-04 Nośniki farmaceutyczne zawierające mirna do zastosowania w leczeniu chorób zwłókieniowych spowodowanych hiperglikemią

Country Status (13)

Country Link
US (2) US10716813B2 (pl)
EP (2) EP3777897B1 (pl)
JP (1) JP7011605B2 (pl)
KR (1) KR102467150B1 (pl)
CN (1) CN109195637B (pl)
AU (1) AU2017260660B2 (pl)
BR (1) BR112018072797A2 (pl)
CA (1) CA3022921A1 (pl)
DK (1) DK3452100T3 (pl)
EA (1) EA037967B1 (pl)
ES (1) ES2861650T3 (pl)
PL (1) PL3452100T3 (pl)
WO (1) WO2017191234A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2906750T3 (es) 2010-05-12 2022-04-20 Prokidney Células renales bioactivas
CA3085662A1 (en) * 2017-12-14 2019-06-20 Unicyte Ev Ag Pharmaceutical carriers containing mirnas for use in the treatment of renal cancer
BR112021002703A2 (pt) 2018-08-31 2021-05-11 Timothy A. Bertram composições compreendendo vesículas derivadas de células e usos das mesmas
CN113966392A (zh) 2019-06-10 2022-01-21 联合细胞Ev股份公司 用于降低细胞衰老的来自人肝干细胞的胞外囊泡(hlsc-ev)
US20240093191A1 (en) * 2021-02-03 2024-03-21 Research Institute At Nationwide Children's Hospital Compositions and methods for treating disease associated with dux4 overexpression
CN115463107A (zh) * 2021-06-10 2022-12-13 中山大学 一种工程化囊泡的制备方法及其应用
US20240309329A1 (en) * 2023-03-17 2024-09-19 MAM Holdings of West Florida, L.L.C. Mesenchymal stem cell-derived exosome drug delivery for cancer and other disorders
CN118975977B (zh) * 2024-08-12 2025-09-23 上海大学 一种靶向工程化细胞外囊泡负载的可注射水凝胶及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2085086A3 (en) * 2000-07-13 2009-11-25 Synvista Therapeutics, Inc. Method for treating congestive heart failure or diabetic nephropathy
WO2006126219A1 (en) 2005-05-26 2006-11-30 Fresenius Medical Care Deutschland G.M.B.H. Liver progenitor cells
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
PT2254586E (pt) * 2008-02-22 2015-05-18 Agency Science Tech & Res Partículas de células estaminais mesenquimais
US8486909B2 (en) * 2009-06-24 2013-07-16 Board Of Regents Of The University Of Nebraska Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease
WO2011057003A2 (en) * 2009-11-04 2011-05-12 Samuil Umansky Methods of using small rna from bodily fluids for diagnosis and monitoring of neurodegenerative diseases
ES2906750T3 (es) 2010-05-12 2022-04-20 Prokidney Células renales bioactivas
EP2603592A2 (en) * 2010-08-13 2013-06-19 The University Court of the University of Glasgow Therapeutic uses of microvesicles and related micrornas
EP3470073A1 (en) * 2012-04-03 2019-04-17 Reneuron Limited Stem cell microparticles
SG11201500329WA (en) * 2012-07-19 2015-02-27 Reneuron Ltd Stem cell microparticles
JP6474394B2 (ja) * 2013-07-05 2019-02-27 ユニベルシテ カトリック ドゥ ルーベン ヒト成体肝臓幹細胞由来の馴化培地および肝臓障害の治療におけるその使用
GB201317887D0 (en) 2013-10-09 2013-11-20 Reneuron Ltd Product
WO2016054094A1 (en) * 2014-09-30 2016-04-07 Research Institute At Nationwide Children's Hospital Compositions and methods for treating hepatic fibrosis
WO2017047800A1 (ja) 2015-09-16 2017-03-23 国立大学法人東北大学 核酸分子

Also Published As

Publication number Publication date
EP3777897B1 (en) 2026-02-11
EA201892536A1 (ru) 2019-04-30
EP3777897A3 (en) 2021-06-09
JP2019514964A (ja) 2019-06-06
DK3452100T3 (da) 2021-03-08
US10716813B2 (en) 2020-07-21
CN109195637B (zh) 2022-08-09
US11110130B2 (en) 2021-09-07
KR102467150B1 (ko) 2022-11-14
BR112018072797A2 (pt) 2019-03-12
US20190209619A1 (en) 2019-07-11
ES2861650T3 (es) 2021-10-06
JP7011605B2 (ja) 2022-01-26
EA037967B1 (ru) 2021-06-16
EP3452100B1 (en) 2020-12-16
AU2017260660B2 (en) 2023-12-21
KR20190005209A (ko) 2019-01-15
CA3022921A1 (en) 2017-11-09
WO2017191234A1 (en) 2017-11-09
EP3452100A1 (en) 2019-03-13
US20200222467A1 (en) 2020-07-16
AU2017260660A1 (en) 2018-12-20
CN109195637A (zh) 2019-01-11
EP3777897A2 (en) 2021-02-17

Similar Documents

Publication Publication Date Title
HUE053309T2 (hu) Új sók és gyógyászati készítmények gyulladásos betegségek kezelésére
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
HRP20181194T1 (hr) Farmaceutski pripravci za liječenje bolesti posredovanih transmembranskim regulatorom provodljivosti cistične fibroze
IL247841A0 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
BR112015002524A2 (pt) derivados de alquilpirimidina para o tratamento de infecções virais e outras doenças.
SI3785717T1 (sl) Postopki za zdravljenje okužb s Coronaviridae
DK3347030T3 (da) Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
EP3448263A4 (en) ELECTROTHERAPEUTIC TREATMENT
HRP20182069T1 (hr) Farmaceutski pripravci za liječenje alzheimerove bolesti
PL3169328T3 (pl) Pochodne chinoliny do leczenia chorób zapalnych
PT3185957T (pt) Patisiran para utilização no tratamento de amoloidose mediada por transtirretina
PT3481846T (pt) 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda
IL252418B (en) Envenomation therapies and related pharmaceutical compositions, systems and kits
SI3346995T1 (sl) Terapevtski sestavek za zdravljenje virusa človeške imunske pomanjkljivosti
BR112016027041A2 (pt) Combinações farmacêuticas para tratamento do câncer
HUE059303T2 (hu) Acetilkolin-észteráz-gátlók bõrbetegségek kezelésére
HUE060496T2 (hu) Terápiás vegyületek és készítmények szociális zavarok és szerhasználati zavarok kezelésére
HUE051296T2 (hu) Benzoxazinon-származékok bõrbetegségek kezelésére
SI3069720T1 (sl) Farmacevtski sestavek, ki vsebuje derivate glutarimida, in njegova uporaba za zdravljenje eozinofilnih bolezni
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
DK3302519T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom
DK3452100T3 (da) FARMACEUTISKE BÆRERE INDEHOLDENDE miRNAer TIL ANVENDELSE I BEHANDLINGEN AF FIBROTISKE SYGDOMME FORÅRSAGET AF HYPERGLYKÆMI
IL248779A0 (en) Pharmaceutical compositions for treating infectious diseases
DK3125874T3 (da) Et terapeutisk middel til anvendelse i behandlingen af infektioner
HRP20181332T1 (hr) Derivati benzimidazola i njihovi farmaceutski pripravci, namijenjeni liječenju upalnih poremećaja